IRF1 and hepatocellular carcinoma: Recently, a study showed that the epigenetic modifier EZH2 can suppress the expression of the immune checkpoint inhibitor PD-L1 by directly upregulating the level of the promoter H3K27me3 for CD274 and IRF1 in hepatoma cells and may serve as a potential therapeutic target for immunotherapy for treating immune-activated HCC (Xiao 2019b).